Oral Carbapenem Wins FDA Approval for cUTIs - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

  • By

  • Kathryn Wighton

  • June 17, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of tebipenem pivoxil for treating complicated urinary tract infections (cUTIs).

Approach:
    Key Findings:
    • Oral tebipenem pivoxil performed similarly to intravenous imipenem-cilastatin.
    • Common adverse reactions included diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.
    Interpretation:

    The FDA has approved tebipenem pivoxil as the first oral carbapenem antibiotic in the US for cUTIs.

    Limitations:
    • Patients with allergies to tebipenem pivoxil or other beta-lactam antibacterials should not take the drug.
    • Not suitable for patients with primary or secondary carnitine deficiency or related metabolic errors.
    Conclusion:

    Tebipenem pivoxil is now available for adults with cUTIs who have limited or no oral treatment options.

    Sources:

Original Source(s)

Oral Carbapenem Wins FDA Approval for cUTIs

  • by Kathryn Wighton

  • June 17, 2026

Related Content

Framework Targets Hospital-Onset UTIs

The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Caries May Signal Oral Antibiotic Resistance

Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.